<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15028">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02002208</url>
  </required_header>
  <id_info>
    <org_study_id>OC000459/017/13</org_study_id>
    <nct_id>NCT02002208</nct_id>
  </id_info>
  <brief_title>Effect of OC000459 on Moderate to Severe Atopic Dermatitis</brief_title>
  <official_title>A Study of the Effect of OC000459 on Signs and Symptoms in Subjects With Moderate to Severe Atopic Dermatitis: A Randomised Double Blind Placebo Controlled Parallel Group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atopix Therapeutics, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atopix Therapeutics, Ltd.</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Austria: Austrian Medicines and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether OC000459 is in reducing disease severity
      and preventing flares in people with moderate to severe atopic dermatitis (AD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include patients with a Th2 high eosinophilic phenotype who typically have
      more severe disease and are prone to flare.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in Eczema Area and Severity Index  (EASI) compared to placebo</measure>
    <time_frame>Baseline, and every 2 weeks for 14 weeks and every 4 weeks for 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Flares (number of flares, time to first flare, time to resolution of flare, number of flare-free days)</measure>
    <time_frame>Baseline, and every 2 weeks for 14 weeks and every 4 weeks for 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>OC000459 Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg orally once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Orally once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC000459</intervention_name>
    <description>None</description>
    <arm_group_label>OC000459 Tablets</arm_group_label>
    <arm_group_label>Placebo Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Atopic dermatitis as defined by a score of at least 9 on the Nottingham Eczema
             Severity Score, stratified into moderate (score 9 to 11 inclusive) and severe (score
             12 to 15 inclusive) disease.

          2. Fully documented history of the use of topical corticosteroids (TCS) and/or topical
             calcineurin inhibitors (TCI). Subjects without a fully documented history will be
             excluded from the study.

          3. Male and female subjects with moderate to severe atopic dermatitis treated with by
             TCS and/or TCI (with or without emollients) at the time of screening and over the
             previous month.

          4. Subjects must have had at least 1 AD flare in the previous 6 months.

        Exclusion Criteria:

          1. Receipt of any forbidden medication including over the counter preparations and
             herbal medicines within 14 days of the first dosing day with the exception of
             paracetamol up to a maximum of 2g daily.

          2. Use of systemic steroids within 4 weeks of the screening visit, light therapy or
             immunosuppressants within 2 months of the screening visit.

          3. Use of NSAIDs.

          4. Subjects initially diagnosed with AD aged 2 years or over will be excluded unless
             they have either coexisting or a history of asthma and/or allergic
             rhinoconjunctivitis.

          5. Subjects with contact dermatitis will be excluded.

          6. Subjects with acute skin infection or acute disease flares. Subjects with active
             flares during the screening to randomisation period (visits 1 to 2) may be managed
             according to normal clinical practice and be rescreened once their flares are no
             longer active.

             -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Bieber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinik Bonn Klinik und Poliklinik für Dermatologie und Allergologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Cork, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Infection and Immunity, The University of Sheffield Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sakari Reitamo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin and Allergy Hospital, Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carle Paul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Larrey - CHU TOULOUSE Service de Dermatologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Regina Folster-Holst</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Schleswig-Holstein,Campus Kiel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roland Kaufmann</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der Johann-Wolfgang-Goethe Universität,Frankfurt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Simon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Leipzig</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Swarna Ekanayake-Bohlig</last_name>
    <role>Principal Investigator</role>
    <affiliation>MENSINGDERMA Research Hamburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Dirschka</last_name>
    <role>Principal Investigator</role>
    <affiliation>CentroDerm GmbH, Heinz-Fangman-Strasse 57, Wuppertal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margitta Worm</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Dermatologie; Charité - Campus Mitte, Luisenstraße 2;10117-Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Malcolm Rustin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Department, Royal Free Hospital, Pond Street,London NW3 2QG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kaija Lammintausta</last_name>
    <role>Principal Investigator</role>
    <affiliation>TYKS T-sairaala, Allergiayksikkö TA2,  Hämeentie 11, 20520 Turku, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain Taieb</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital saint André - CHU BORDEAUX Service de Dermatologie, 1 rue Jean Burguet, 33075-Bordeaux,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Wollenberg</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik und Poliklinik für Dermatologie &amp; Allergologie der LMU München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernhard Homey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Düsseldorf, Hautklinik,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Athanasios Tsianakas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätstklinikum Münster; Klinik &amp; Poliklinik für Hautkrankheiten;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alison Layton</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harrogate &amp; District NHS Foundation Trust, Lancaster Park Road,HG2 7SX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincent Piguet</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept Dermatology &amp; Wound Healing,3rd floor, Glamorgan House,  University Hospital of Wales, Heath Park, Cardiff,CF14 4XN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine Goujon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Lyon Sud - Unité de Recherche en Immunologie, Secteur 1 - Pavillon 1 K 165, chemin du Grand Revoyet,69495-Pierre Benite Cedex, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Kalscheuer</last_name>
    <phone>+49 221 5999247</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heidrun Budde</last_name>
    <phone>+49 221 5999240</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Professor Michael Cork</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Cork</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>November 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
